logo-loader
RNS
Vulcan Two Group plc

Director/PDMR Transaction

RNS Number : 7949Y
Molecule Group PLC
13 October 2026
 

Molecule Group plc

(the “Company”, “Group” or “Molecule”)

 

Director/PDMR Transaction

 

Molecule Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, announces that Brendan O’Brien, Chief Operating Officer, has acquired a total of 41,500 ordinary shares of 10 pence each in the Company ("Ordinary Shares") at an average price of £2.13 per Ordinary Share. Following the purchases, Mr O’Brien holds 591,500 Ordinary Shares, representing 2.2% of the Company’s issued share capital.

 

The Notification of Dealings are set out below.

 

The following transactions have been notified to the Company pursuant to Article 19.1(a) of the UK Market Abuse Regulation ("MAR"). This notification is issued in accordance with Article 19.3 of MAR.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Brendan O’Brien

2

Reason for the notification

a)

Position/Status:

 

Chief Operating Officer

b)

Initial Notification/Amendment:

 

Initial Notification

3

Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor

a)

Name:

Molecule Group plc

b)

LEI:

213800W5TPGBRC2V7L20

4.

Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.

a)

Description of the financial instrument:

 

Ordinary Shares of 10 pence each

 

b)

Identification code:

ISIN: GB00BTQLZH16

 

b)

Nature of the transaction:

 

Acquisition of Ordinary Shares

c)

Price(s) and volume(s):

 

Price

Volume

£2.14

18,300

 

d)

Aggregated volume:

Price:

Single Transaction

e)

Date of the Transaction:

08-10-2026

f)

Place of the Transaction:

XLON:AIM

4.

Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.

a)

Description of the financial instrument:

 

Ordinary Shares of 10 pence each

 

b)

Identification code:

ISIN: GB00BTQLZH16

 

b)

Nature of the transaction:

 

Acquisition of Ordinary Shares

c)

Price(s) and volume(s):

 

Price

Volume

£2.12

23,200

 

d)

Aggregated volume:

Price:

Single Transaction

e)

Date of the Transaction:

12-10-2026

f)

Place of the Transaction:

XLON:AIM

 

 

For further information please contact:

 

Molecule Group plc

Michael Kraftman, Chief Executive Officer

Keith Butcher, Chief Finance Officer

Brendan O’Brien, Chief Operating Officer

investors.molecule.co.uk

Email: corporate@molecule.co.uk

Canaccord Genuity Limited
(Nominated Adviser and Sole Broker)

Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott

Tel: +44 (0) 20 7523 8000
 

Alma Strategic Communications
(Financial PR)

Justine James / Sam Modlin / Will Merison

Email: molecule@almastrategic.com

Tel: +44 (0) 20 3405 0205

 

Notes to Editors

Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFFFIFLVLIR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read